WO2009006089A3 - Agonistes des récepteurs d'adénosine a2 - Google Patents

Agonistes des récepteurs d'adénosine a2 Download PDF

Info

Publication number
WO2009006089A3
WO2009006089A3 PCT/US2008/067978 US2008067978W WO2009006089A3 WO 2009006089 A3 WO2009006089 A3 WO 2009006089A3 US 2008067978 W US2008067978 W US 2008067978W WO 2009006089 A3 WO2009006089 A3 WO 2009006089A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine receptor
receptor agonists
formula
agonists
restenosis
Prior art date
Application number
PCT/US2008/067978
Other languages
English (en)
Other versions
WO2009006089A2 (fr
Inventor
Kenneth A Jacobson
Zhan-Guo Gao
Hayamitsu Adachi
James M Downey
Yanping Liu
Original Assignee
Us Gov Health & Human Serv
Univ South Alabama
Kenneth A Jacobson
Zhan-Guo Gao
Hayamitsu Adachi
James M Downey
Yanping Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ South Alabama, Kenneth A Jacobson, Zhan-Guo Gao, Hayamitsu Adachi, James M Downey, Yanping Liu filed Critical Us Gov Health & Human Serv
Publication of WO2009006089A2 publication Critical patent/WO2009006089A2/fr
Publication of WO2009006089A3 publication Critical patent/WO2009006089A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des agonistes des récepteurs d'adénosine AZB (AR) de formule (I), R1, R2, R3, R4, Z, et n étant définis dans la présente. L'invention propose également des compositions comprenant au moins un composé de formule I et des procédés pour leur utilisation, par exemple, dans le traitement du choc septique, de la fibrose kystique, de la resténose, de la dysfonction érectile, de l'inflammation, de l'ischémie myocardique, et de la lésion de reperfusion.
PCT/US2008/067978 2007-06-29 2008-06-24 Agonistes des récepteurs d'adénosine a2 WO2009006089A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94706607P 2007-06-29 2007-06-29
US60/947,066 2007-06-29
US95025007P 2007-07-17 2007-07-17
US60/950,250 2007-07-17

Publications (2)

Publication Number Publication Date
WO2009006089A2 WO2009006089A2 (fr) 2009-01-08
WO2009006089A3 true WO2009006089A3 (fr) 2009-04-09

Family

ID=39952379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067978 WO2009006089A2 (fr) 2007-06-29 2008-06-24 Agonistes des récepteurs d'adénosine a2

Country Status (1)

Country Link
WO (1) WO2009006089A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2014024195A1 (fr) * 2012-08-09 2014-02-13 Can-Fite Biopharma Ltd. Ligands du récepteur a3 de l'adénosine pour l'utilisation dans le traitement d'un dysfonctionnement sexuel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002553A2 (fr) * 1994-07-14 1996-02-01 Glaxo Group Limited DERIVES AMINO PURINE-β-D-RIBOFURANURONAMIDE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002553A2 (fr) * 1994-07-14 1996-02-01 Glaxo Group Limited DERIVES AMINO PURINE-β-D-RIBOFURANURONAMIDE

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADACHI, H. ET AL.: "Structure-activity relationship of 2,N6,5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor", J. MED. CHEM., vol. 50, April 2004 (2004-04-01), pages 1810 - 1827, XP002504703 *
BARALDI ET AL: "N6-[(Hetero)aryl/(cyclo)alkyl-carbamoyl- methoxy-phenyl]-(2-chloro)- 5'-N-ethylcarboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 15, no. 7, 12 March 2007 (2007-03-12), pages 2514 - 2527, XP005922442, ISSN: 0968-0896 *
BARALDI, P.G. ET AL.: "Synthesis and Biological Evaluation of Novel 1-Deoxy-1-[6-[((hetero)arylcarbonyl) hydrazino]- 9H-purin-9-yl]-N-ethyl-?-d-ribo furanuronamide Derivatives as Useful Templates for the Development of A2B Adenosine Receptor Agonists", J. MED. CHEM., vol. 50, 2007, pages 374, XP002513993 *
UEEDA M ET AL: "2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 34, no. 4, 1 April 1991 (1991-04-01), pages 1340 - 1344, XP002961133, ISSN: 0022-2623 *
ZHAN-GUO GAO ET AL: "2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 68, 2004, pages 1985 - 1993, XP002453822, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2009006089A2 (fr) 2009-01-08

Similar Documents

Publication Publication Date Title
TW200638933A (en) Compounds for inflammation and immune-related uses
NO20071095L (no) Hittil ukjente tiofenderivater
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200716108A (en) Thiophene compounds for inflammation and immune-related uses
TW200738670A (en) Novel thiophene derivatives
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
MY154909A (en) Novel thiophene derivatives
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
IL192948A0 (en) Novel pyridine derivatives
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
TW200637840A (en) Compounds for inflammation and immune-related uses
WO2006091898A3 (fr) Xanthines substituees par pyrazolyle
WO2008049123A8 (fr) Compositions et procédés pour l'inhibition de la voie jak
WO2006034402A3 (fr) Composes pour l'inflammation et applications associees aux troubles immuns
WO2007002559A8 (fr) Modulateurs des lxr a base de pyrazoles
CL2011000480A1 (es) Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras.
WO2006061417A3 (fr) Derives de quinazoline mtki
WO2006133426A3 (fr) Compositions et procedes d'inhibition de la voie jak
MX2010004576A (es) Derivados de pirimidina novedosos.
WO2009016462A3 (fr) Bicyclolactames substitués
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
WO2007064553A3 (fr) Derives de thiazole comme modulateurs de recepteurs cxcr3
DK1881985T3 (da) Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771786

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771786

Country of ref document: EP

Kind code of ref document: A2